Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Design Therapeutics Q3 2026 Results: Net Loss of $20.3M, Loss Widens

Design Therapeutics reported a net loss of $20.3 million for the third quarter of 2026, driven by $22.2 million in operating expenses primarily for R&D. The company maintained a strong liquidity position with $208.6 million in cash and investments, which management expects will fund operations for at least 12 months.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-20.3-17.0
EPS (diluted, $ a share)$-0.32$-0.30

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: DSGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Design Therapeutics, Inc.: key numbers

Share price
$9.84Close, Nov 17
Market cap
$630M
Shares outstanding
64.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Design Therapeutics, Inc.

All →
4:10 PM ET 8-K
Financial Results

Design Therapeutics Financial Results

Design Therapeutics reported third quarter 2026 financial results, posting a net loss of $20.3 million. The company ended the period with $208.6 million in cash and securities, which it expects will provide a strong financial runway for its clinical-stage GeneTAC programs. Key upcoming milestones include a registrational plan update for DT-216P2 in Q4 2026 and 12-week clinical data in Q1 2027.

“We remain focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia. In DM1, our Phase 1 trial of DT-818 is evaluating an approach designed to selectively reduce transcription of the mutant DMPK allele, targeting the source of toxic RNA. Clinical readouts expected in 2027 will help guide these programs as we pursue our vision for the GeneTAC® platform: to address the underlying causes of serious genetic diseases and deliver meaningful benefits for patients.”

Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.